TissueGen Wins 2017 Future Textiles Award for Most Innovative Small Company

DALLAS, May 18, 2017 (GLOBE NEWSWIRE) — TissueGen® Inc., developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, nerve regeneration, and tissue engineering, was awarded the title of Most Innovative Small Size Company by the World Textile Information Network (WTiN), publisher of international technical textiles magazine Future Textiles (formerly known as Future Materials).

TissueGen Founder and CSO, Dr. Kevin Nelson, and President and CEO, Christopher Knowles, accepted the award at the Future Textiles Award Gala in Frankfurt, Germany this past week. Organized by WTiN, the third edition of the biennial awards celebrated the best innovations in the technical textiles industry.

TissueGen’s patented process for manufacturing commercially available ELUTE® fiber occurs at or below body temperature thereby preserving the biologic activity of incorporated biologics and pharmaceutical compounds.  ELUTE fiber technology enables controlled sustained delivery of a broad range of sensitive biologics and pharmaceuticals directly at the topical application or implant site and may potentially orchestrate and improve the healing process.  ELUTE fiber enables tissue engineering and regenerative medicine applications never before possible.

“We are honored to receive this recognition from WTiN as further testament to the groundbreaking work conducted by our scientists at TissueGen,” said Knowles. “We were privileged to participate in this special event and congratulate all the winners and finalists.”

A full list of winners is available here.

About TissueGen
TissueGen® Inc. is the developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, nerve regeneration, and tissue engineering. TissueGen manufactures biodegradable polymer-based fibers with the broadest drug delivery capabilities available today. ELUTE fiber can directly replace standard fibers used in medical devices currently on the market and may provide significantly improved clinical outcomes by delivering sensitive therapeutic agents directly at the implant or topical application site in controlled, sustained release profiles. ELUTE fiber may enable medical device developers to guide the body’s healing and regenerative processes.
For more information, please visit www.tissuegen.com.

CONTACT: For more information contact: 
Jordan Bouclin
SVM Public Relations
401-490-9700
jordan.bouclin@svmpr.com

Logo Header Menu